- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-9378
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
PARP inhibitors: current status and implications for anticancer therapeutics ; volume:8 ; number:1 ; day:2 ; month:12 ; year:2013 ; pages:1-3 ; date:12.2013
Infectious agents and cancer ; 8, Heft 1 (2.12.2013), 1-3, 12.2013
- Creator
-
Usmani, Hadi
- Contributor
-
Hussain, Syed Ather
Sheikh, Asfandyar
SpringerLink (Online service)
- DOI
-
10.1186/1750-9378-8-46
- URN
-
urn:nbn:de:1111-2016072626262
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Usmani, Hadi
- Hussain, Syed Ather
- Sheikh, Asfandyar
- SpringerLink (Online service)
Other Objects (12)
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
PARP inhibitors
Akt inhibitors: mechanism of action and implications for anticancer therapeutics
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments
Targeting CDK9 for anti-cancer therapeutics
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
Advances and perspectives of PARP inhibitors
PARP inhibitors in the management of breast cancer: current data and future prospects
Mitophagy in carcinogenesis, drug resistance and anticancer therapeutics
PARP Inhibitors in Ovarian Cancer: A Review
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
PARP inhibitors
Akt inhibitors: mechanism of action and implications for anticancer therapeutics
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments
Targeting CDK9 for anti-cancer therapeutics
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
Advances and perspectives of PARP inhibitors
PARP inhibitors in the management of breast cancer: current data and future prospects
Mitophagy in carcinogenesis, drug resistance and anticancer therapeutics
PARP Inhibitors in Ovarian Cancer: A Review
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
PARP inhibitors
Akt inhibitors: mechanism of action and implications for anticancer therapeutics
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments
Targeting CDK9 for anti-cancer therapeutics
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
Advances and perspectives of PARP inhibitors
PARP inhibitors in the management of breast cancer: current data and future prospects
Mitophagy in carcinogenesis, drug resistance and anticancer therapeutics